Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of a 6 mg twice a day dose of an investigational product in subjects with diabetic neuropathy


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00548925
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 2
Start date November 2007
Completion date December 2008

See also
  Status Clinical Trial Phase
Completed NCT02783469 - Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Completed NCT05563454 - A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants Phase 1
Not yet recruiting NCT04137328 - Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide N/A
Completed NCT00452777 - Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain Phase 2
Withdrawn NCT05406219 - A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function Phase 1
Active, not recruiting NCT05351801 - Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain Phase 2
Completed NCT04454424 - Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function Phase 1
Recruiting NCT05986292 - A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain Phase 2
Terminated NCT00619983 - Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Phase 4
Completed NCT04265781 - Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants Phase 1
Completed NCT06336486 - the Effectiveness of Intermittent Pneumatic Compression on Neuropathic Pain in Patients With Diabetic Polyneuropathy N/A
Completed NCT04487431 - A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B) Phase 1
Completed NCT04471337 - Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function Phase 1
Completed NCT01589432 - A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy Phase 2
Terminated NCT01579279 - A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain Phase 2
Completed NCT01345045 - A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain Phase 2